Dravet syndrome is a rare but severe form of epilepsy that begins in infancy, challenging families and neurodegenerative disease researchers alike to find effective treatments
Overview: A Massachusetts biopharma company developing therapeutics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease was able to accelerate their pre-clinical development by partnering
Summary: Gut microbiota impacts nearly every aspect of health, but researching it can be tricky due to differences between humans and commonly used model organisms,
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.